Jin-kui Yang

发表

Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial

Wenhua Xiao, Qing Tian, Jin Yang, 2020, Acta Diabetologica.

Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS).

M. Zhang, Jun Liu, Xuefeng Yu, 2021, Science bulletin.

Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients

Gangyi Yang, Jin-kui Yang, Yongde Peng, 2017, Journal of diabetes.

Management status of type 2 diabetes mellitus in tertiary hospitals in Beijing: gap between guideline and reality.

Jin-kui Yang, Ju-ming Lu, Xiao-hui Guo, 2012, Chinese medical journal.

Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.

Lulu Chen, Zhi-Min Liu, Jin-kui Yang, 2009, Chinese medical journal.

Efficacy and Safety of Avandamet or Uptitrated Metformin Treatment in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Controlled Trial

H. Tian, Ying-li Chen, Jin-kui Yang, 2015, Chinese medical journal.

Clinical Study on Rosiglitazone Monotherapy of Early Type 2 Diabetes

Jin-kui Yang, Dequan Wang, Yangang Wang, 2002 .

A multicenter, randomized, open, controlled clinical trial of isophane protamine biosynthetic human insulin injection in the treatment of diabetes mellitus

Jin-kui Yang, Xiangjin Xu, Yong He, 2011 .